A Randomized Phase III Study of Doxorubicin Versus Cisplatin/Interferon α-2b/Doxorubicin/Fluorouracil (PIAF) Combination Chemotherapy for Unresectable Hepatocellular Carcinoma

A Randomized Phase III Study of Doxorubicin Versus Cisplatin/Interferon α-2b/Doxorubicin/Fluorouracil (PIAF) Combination Chemotherapy for Unresectable Hepatocellular Carcinoma

Background: Single-agent doxorubicin has been widely used to treat unresectable hepatocellular carcinoma (HCC), but the response rate is low (

Saved in:
Bibliographic Details
Published in:JNCI : Journal of the National Cancer Institute 2005-10, Vol.97 (20), p.1532-1538
Main Authors: Yeo, Winnie, Mok, Tony S., Zee, Benny, Leung, Thomas W. T., Lai, Paul B. S., Lau, Wan Y., Koh, Jane, Mo, Frankie K. F., Yu, Simon C. H., Chan, Anthony T., Hui, Pun, Ma, Brigette, Lam, Kwok C., Ho, Wing M., Wong, Herman T., Tang, Amanda, Johnson, Philip J.
Format: Article
Language:eng
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Single-agent doxorubicin has been widely used to treat unresectable hepatocellular carcinoma (HCC), but the response rate is low (
ISSN:0027-8874
1460-2105